Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium-68 DOTA-TOC Imaging for Somatostatin Receptor Positive Tumors
NCT02177773Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Jun 2014
- Primary completion
- Aug 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of gallium Ga 68-edotreotide in Neuroendocrine Neoplasm (NEN), Paraganglioma (PGL), Carcinoid Tumor (CT), neuroblastoma, sponsored by University of California, San Francisco. Started Jun 2014; status: terminated.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)Paraganglioma (PGL)Carcinoid Tumor (CT)neuroblastoma
Beyond the preview
Go deeper on NCT02177773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177773.